Dr. Sarita Rani Jaiswal

Consultant, Dept. of BMT and Hematology
BSc, MBBS, Fellowship in Critical Care Medicine, MD
Fellowship in BMT (India), Fellowship in BMT (Italy)
Visiting Physician (Fred Hutch Cancer Centre, SCCA, Seattle, USA)

Membership of International Societies

  • American Society Of Blood And Marrow Transplantation (ASBMT)
  • European Hematology Association (EHA)
  • Asia Pacific Hematology Consortium (APHCON)

Brief Profile

Dr. Sarita Rani Jaiswal trained in Internal Medicine, Critical Care Medicine and Pathology before initiating her career in Hemato-Oncology and BMT. Dr. Jaiswal trained in BMT for three years including fellowships in Italy at University of Parma under Prof Franco Aversa and San Martino Hospital at Genova under Prof Andrea Bacigalupo. She has also received a fellowship as a Visiting Physician at Fred Hutchinson Cancer Research Centre, Seattle, USA.

Dr. Jaiswal has been instrumental in developing the Haploidentical BMT program led by Dr. Suparno Chakrabarti at Apollo Gleneagles Hospital, Kolkata. This has been the first such transplant program in India. She has made several international presentations and publications in this field in the last 12 months. Dr. Jaiswal has made significant contribution in the field of NK cell research in patients undergoing Haploidentical BMT for Aplastic Anemia.

Dr. Sarita Jaiswal has also trained exclusively in TCRalfabeta depleted Haploidentical BMT under Prof Aversa, who is a pioneer in this field. Dr. Jaiswal has been awarded the ESH-EBMT scholarship for her work in Haploidentical BMT.

Dr. Sarita Jaiswal shall be leading the TCRalfabeta depleted Haploidentical BMT Program at Dharamshila Hospital. This is first such BMT program in India.

Presentations

  • Jaiswal S et al. A case series of Myoepithelioma of Minor Salivary Glands With significance of IHC. MAPCON, India, 2009
  • Jaiswal S et al.Contrasting Patterns of Alloreactivity Amongst Malignant and Nonmalignant Diseases Receiving Haploidentical PBSC GRAFT and Post-Transplant Cyclophosphamide. (Poster no 473). 2013 BMT tandem meeting.
  • Jaiswal S et al. Persistently High GAM Levels Are Associated with Nonrelapse Mortality in HCT Recipients Irrespective of Invasive Aspergillosis: A Prospective Cohort Study. (Poster no 305). 2013 BMT tandem meeting.
  • Jaiswal S et al. Second Haploidentical PBSC Transplantation From the Same Donor After Early Relapse without Gvhd in Patients with Acute Leukemia. (Poster no 474). 2013 BMT tandem meeting.
  • Jaiswal S et al. Is Haploidentical Family Donor Transplantation The Best Form Of Alternative Donor HCT In Developing Countries? BTG 2013, Hongkong. Jaiswal S. Is Haploidentical Family Donor Transplantation The Best Form Of Alternative Donor HCT In Developing Countries? (ORAL PRESENTATION) ESH EBMT TRAINING COURSE ON HCT, ITALY, APRIL 2013.
  • Jaiswal S. NK Alloreactive Donor Is Associated With Reduced Relapse In Refractory AML But High Nonrelpase Mortality In Patients With Aplastic Anemia Following T-Replete Haploidentical PBSCT With Post Transplant. 18th Congress of EHA, 2013.
  • Jaiswal S et al. Comparable Outcome Of Haploidentical And Matched Sibling Donor Peripheral Blood Stem Cell Transplantation For High Risk Aplastic Anemia. 1st International Workup on Haploidentical Transplantation, 2013.
  • Jaiswal S et al. Comparable Outcome Of Haploidentical And Matched Sibling Donor Peripheral Blood Stem Cell Transplantation Following Myeloablative Conditioning For Poor Risk Acute Myeloid Leukemia. 1st International Workup on Haploidentical Transplantation, 2013.
  • Jaiswal S. Natural Killer Cells: A New Weapon in The Armamentarium. National Cancer Congress, 2014, DHRC, Delhi, 2014.
  • Jaiswal S et al. Outcome Of Haploidentical PBSC Transplantation For High Risk Aplastic Anemia With Post-Transplant Cyclophosphamide Is Similar To Matched Sibling PBSCT And Depends On Choice Of Donors: Adverse Effect Of Natural Killer Cell Alloreactivity. 40th Annual Meeting of the European Society for Blood and Marrow Transplantation: April 2014 . Milan, Italy
  • Jaiswal S et al. Comparable Outcome Of Haploidentical And Matched Sibling Donor Peripheral Blood Stem Cell Transplantation Following Myeloablative Conditioning For Poor Risk Acute Myeloid Leukemia. 40th Annual Meeting of the European Society for Blood and Marrow Transplantation: April 2014. Milan, Italy

Publications

  • Jaiswal S et al.Contrasting Patterns of Alloreactivity Amongst Malignant and Nonmalignant Diseases Receiving Haploidentical PBSC GRAFT and Post-Transplant Cyclophosphamide. BBMT. 2013; 19:S346
  • Jaiswal S et al. Persistently High GAM Levels Are Associated with Nonrelapse Mortality in HCT Recipients Irrespective of Invasive Aspergillosis: A Prospective Cohort Study. BBMT. 2013; 19:S264
  • Jaiswal S et al. Second Haploidentical PBSC Transplantation From the Same Donor After Early Relapse without Gvhd in Patients with Acute Leukemia. BBMT. 2013; 19:S264.
  • Jaiswal S et al. Is Haploidentical Family Donor Transplantation The Best Form Of Alternative Donor HCT In Developing Countries? Leukemia & Lymphoma Jun 2013, Vol. 54, No. S1: 3–31
  • Jaiswal S. NK Alloreactive Donor Is Associated With Reduced Relapse In Refractory AML But High Nonrelpase Mortality In Patients With Aplastic Anemia Following T-Replete Haploidentical PBSCT With Post Transplant. HEMATOLOGICA; 2013: 98 (S1); 159.
  • Jaiswal S, Chatterjee S, Chakrabarti S. Paternal Bone Marrow Infusion As Salvage Therapy For Severe Gvhd Following Maternal Haploidentical Transplantation Resulting In Biparental Chimersim. INT J HEMATOL, 2013 (Accepted for publication).
  • Jaiswal S, et al. Adverse Effect Of Natural Killer Cell Alloreactivity In Patients With Severe Aplastic Anemia Receiving Haploidentical Pbsc Graft And Post-Transplant Cyclophosphamide (Accepted for Publication)

Post Your Query